Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 139-144 , 15 February 2003

Clinical–MRI correlations in the secondary progressive phase of MS: lessons from the treatment trials

  • M Clanet
    • ,
  • E Cassol
    • ,
  • C Manelfe
    • ,
  • I Berry

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, CHU Rangueil, F31403 Toulouse Cedex 4, France. Tel.: +33-561-32-28-70; fax: +33-561-32-27-54.

References 

  1. Miller DH, Grossman RI, Reingold SC, Mc Farland HF. The role of MR techniques in understanding and managing MS. Brain. 1998;121:3–24
  2. Trapp BD, Peterson J, Ransohoff RM, et al.  Axonal transection in the lesions of MS. N. Engl. J. Med. 1998;338:278–285
  3. Kappos L, Polman C, Pozzilli C, et al.  Final analysis of the European multicenter trial on IFN beta-1b in SP MS. Neurology. 2001;57:1969–1975
  4. Miller DH, Molyneux PD, Barker GJ, et al.  Effect of IFN beta-1b on MRI outcomes in SP MS: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann. Neurol. 1999;46:850–859
  5. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group . Randomized controlled trial of Interferon-beta-1a in SP MS: clinical results. Neurology. 2001;56:1496–1504
  6. Li DKB, Zhao GJ, Paty DW, et al.  Randomized controlled trial of Interferon-beta-1a in SP MS: MRI results. Neurology. 2001;56:1505–1513
  7. Paty DW, Li DKB  The UBC Study Group  IFNB MS Study Group . Interferon beta-1b is effective in RR MS: 2. MRI analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662–667
  8. PRISMS Study Group . Randomized double-blind placebo-controlled study of interferon beta-1a in RR MS. Lancet. 1998;352:1498–1504
  9. Goodkin DE  North American SP MS Study Group . Interferon beta-1b in SP MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology. 2000;54:2352; [Abstract]
  10. Stone LA, Frank JA, Albert PS, et al.  The effect of interferon beta on BBB disruptions demonstrated by contrast enhanced MRI in RR MS. Ann. Neurol. 1995;37:611–619
  11. van Walderveen MA, Kamphorst W, Scheltens P, et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in MS. Neurology. 1998;50:1282–1288
  12. Barkhof F, van Waesberghe JHT, Filippi M, et al.  T1 hypointense lesions in SP MS: effect of interferon beta-1b treatment. Brain. 2001;124:1396–1402
  13. Truyen L, van Waesberghe JHT, van Walderveen MA, et al.  Accumulation of hypointense lesions (black holes) on T1 spin-echo MRI correlates with disease progression in MS. Neurology. 1996;47:1469–1476
  14. Bitsch A, Kuhlman T, Stadelmann C, et al.  A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann. Neurol. 2001;49:793–796
  15. Brex PA, Molyneux PD, Smiddy P, et al.  The effect of interferon beta-1b on the evolution of enhancing lesions in SP MS. Neurology. 2001;57:2185–2190
  16. Lossef NA, Wang L, Lai HM, et al.  Progressive cerebral atrophy in MS: a serial MRI study. Brain. 1996;119:2009–2019
  17. Rudick RA, Fisher E, Lee JC, et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in RR MS. Neurology. 1999;53:1698–1704
  18. Rudick RA, Fisher E, Lee JC, et al.  Brain atrophy in relapsing MS: relationship to relapses, EDSS and treatment with interferon beta 1a. Mult. Scler. 2000;6:365–372
  19. Molyneux PD, Kappos L, Polman C, et al.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in SP MS. Brain. 2000;123:2256–2263
  20. Kalkers NF, Bergers E, Castelijns JA, et al.  Optimizing the association between disability and biological markers in MS. Neurology. 2001;57:1253–1258
  21. van Waesberghe JH, Kamphorst W, De Groot CJ, et al.  Axonal loss in MS lesions: MRI insights into substrates of disability. Ann. Neurol. 1999;46:747–754
  22. Bagley LJ, Grossmann RI, Galetta SL, et al.  Characterisation of white matter lesions in MS and traumatic brain injury as revealed by magnetisation transfer contours plots. AJNR Am. J. Neuroradiol. 1999;20:977–981
  23. Gass A, Barker GJ, Kidd D, et al.  Correlation of MTR with clinical disability in MS. Ann. Neurol. 1994;36:62–67
  24. Dehmeshki J, Silver NC, Leary SM, et al.  Magnetisation transfer ratio histogram analysis of primary progressive and other MS subgroups. J. Neurol. Sci. 2001;185:11–17
  25. Filippi M, Ianucci G, Tortorella C, et al.  Comparison of MS clinical phenotypes using conventional and magnetisation transfer MRI. Neurology. 1999;52:588–594
  26. Tortorella C, Viti B, Bozzali M, et al.  A magnetisation transfer histogram study of normal appearing brain tissue in MS. Neurology. 2000;54:186–193
  27. Rovaris M, Bozzali M, Santuccio G, et al.  In vivo assessment of the brain and cervical cord pathology of patients with primary progressive MS. Brain. 2001;124:2540–2549
  28. Tourbah A, Stievenart JL, Gout O, et al.  Localised proton magnetic resonance spectroscopy in RR versus SP MS. Neurology. 1999;53:1091–1097
  29. Arnold DL. Magnetic resonance spectroscopy: imaging axonal damage in MS. J. Neuroimmunol. 1999;98:2–6
  30. Rovaris M, Filippi M. The value of new magnetic resonance techniques in MS. Curr. Opin. Neurol. 2000;13:249–254
  31. Horsfield MA, Lai M, Webb SL, et al.  Apparent diffusion coefficients in benign and SP MS by nuclear MR. Magn. Reson. Med. 1996;36:393–400
  32. Droogan AG, Clark CA, Werring DJ, et al.  Comparison of MS clinical subgroups using navigated spin-echo diffusion weighted imaging. Magn. Reson. Imag. 1999;17:653–661
  33. Werring DJ, Brassat D, Droogan AG, et al.  The pathogenesis of lesions and NAWM changes in MS: a serial diffusion MRI study. Brain. 2000;123:1667–1676
  34. Nusbaum AO, Tang CY, Wei TC, et al.  Whole-brain diffusion MR histograms differ between MS subtypes. Neurology. 2000;54:1421–1426
  35. Mainero C, De Stefano N, Iannucci G, et al.  Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology. 2001;56:1331–1334

PII: S0022-510X(02)00351-9

Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 139-144 , 15 February 2003

Article Tools

* Image Usage & Resolution